Streetbeat News

Regulatory

META

Veteran trader Peter Brandt suspects his posts on X (formerly Twitter) are being censored due to his views on voting and COVID fraud, inspired by an interview with Mike Benz. Elon Musk has also accused Meta Platforms Inc. (META) of censorship, particularly around election integrity.

Portfolio Pulse from Benzinga Neuro

February 20, 2024 | 12:39 pm

CCM

Concord Medical Services Holdings Limited (CCM) received a non-compliance letter from the NYSE due to its American Depositary Share's trading price falling below the required minimum. The company must address this issue to regain compliance and avoid potential delisting.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:37 pm

RAPT

Rapt Therapeutics has been informed by the FDA of a clinical hold on its Phase 2B trial of Zelnecirnon in atopic dermatitis and its Phase 2A trial in asthma due to a serious adverse event of liver failure in one patient. Dosing and enrollment have been halted in both trials. The hold does not affect RAPT's oncology trial of tivumecirnon.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:35 pm

CMND

SPRC

Clearmind Medicine Inc. has submitted three international patent applications for psychedelic-based compounds, in collaboration with SciSparc Ltd., under the Patent Cooperation Treaty. These efforts are part of their ongoing partnership to develop therapies for central nervous system disorders.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:17 pm

CMMB

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) announced that Brazil and Israel Patent Offices have granted new patents for CM-101, its monoclonal antibody for fibro-inflammatory diseases. CM-101, targeting CCL24, is in a global Phase 2 trial for primary sclerosing cholangitis with results expected by mid-2024.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:10 pm

DFIN

Donnelley Financial (DFIN) announced it is identifying opportunities arising from new regulations, including tailored shareholder reports, and is preparing to help clients comply with upcoming regulatory changes.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 12:08 pm

KALV

KalVista Pharmaceuticals announced that the UK's MHRA has awarded an Innovation Passport for Sebetralstat, a novel oral treatment for Hereditary Angioedema. This is the initial step in the ILAP, aimed at accelerating market access for innovative medicines.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:56 am

FAT

FAT Brands has stated in a filing that all conduct related to the SEC investigation and the Wells Notices they received pertains to activities that occurred during or before the fiscal year 2020. This indicates that the issues under investigation are not recent but are tied to past financial periods.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:53 am

FAT

On February 15, 2024, FAT Brands, its CEO Andrew Wiederhorn, and one current and one former officer received a 'Wells Notice' from the SEC, indicating potential securities law violations.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:53 am

MRK

Merck announced that the FDA has granted priority review to its application for KEYTRUDA, in combination with chemotherapy, as a treatment for primary advanced or recurrent endometrial carcinoma. This development could potentially enhance Merck's oncology portfolio and strengthen its position in the cancer treatment market.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 11:46 am